stockrow
Friday 6 November 2026
Export NORD’s income statement to Excel — free account
Nordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
3.40
0.33
−8.85%
Follow NORD
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (8.06%) | (6.45%) | (7.37%) | (11.40%) |
+8 more TTM periods Free account |
|
| (6.80%) | (5.49%) | (6.71%) | (10.06%) | ||
ROIC |
(4.43%) | (4.25%) | (3.92%) | (4.07%) | |
Return on Tangible Assets |
372.88% | 635.19% | 1,763.66% | 944.21% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.21) | (0.12) | (0.10) | (0.04) | |
Free Cash Flow |
(4.07) | (2.24) | (1.87) | (0.70) | |
Capital Expenditures |
(0.01) | 2.08 | 2.17 | 2.17 | |
| Other line items | |||||
Cash ROIC |
(6.62%) | (3.49%) | (2.88%) | (1.09%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,743.52) | (5,463.87) | (10,135.25) | (20,986.00) | |
Operating CF/Net income |
0.80 | 1.08 | 0.89 | 0.59 | |
Depreciation/Fixed assets |
0.77 | 0.83 | 0.00 | 0.88 | |
Capex/Depreciation |
(1.75) | 306.00 | 246.25 | 318.85 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.24) | (0.22) | (0.16) | |
Capex per Share |
0.00 | 0.11 | 0.12 | 0.12 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026